SummaryIndia has launched Dendrite Dx, its first FDA-approved non-invasive test for Alzheimer’s detection. Offered by Dr Dangs Labs, it combines a cognitive assessment, blood biomarkers, and an APS2 score to estimate amyloid plaque risk. Expected to cost around ₹10,000, the test enables early, reliable diagnosis, reducing dependence on invasive lumbar punctures or costly scans.